Jan. 24, 2025 — A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical ...
Only 45.5% of patients completed guideline-concordant surveillance within 30 months after treatment for high-grade cervical ...
Hosted on MSN1mon
A therapeutic HPV vaccine could eliminate precancerous cervical lesions, clinical trial suggestsA therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a Phase II clinical trial ...
Abstract Thinking and Statins With Immune Checkpoint Inhibitors: Enough to Change Clinical Practice? Using an index designed and validated for use in ANCHOR, HRQoL was assessed before random ...
A total of 246 cases with objective evidence of benign cervical lesions were divided into 2 ... as compared with patients in group B, who reported high satisfaction (77.5%) and good tolerability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback